Cotargeting the positive regulators of these reciprocal crosstalk mechanisms, such as PI3K, AKT, G6PD and nucleotide synthesis37–42 may be an effective treatment for cancers with PTEN loss or PI3K activation. This evidence concerns the gene AKT1 and cancer.